STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · VIMIAN.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Vimian Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vimian Group AB (publ)’s next earnings report is currently expected on Feb 11, 2027, with estimated earnings per share of SEK 0.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vimian Group AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 18, 2025 | SEK 0.32+11.78% vs estimate | SEK 1.17B-1.97% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | SEK 0.22-3.37% vs estimate | SEK 1.17B+0.17% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | SEK 0.26-4.65% vs estimate | SEK 1.21B+5.72% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 279.50+SEK 2.00 (+0.72%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 670.00SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 319.40-SEK 0.80 (-0.25%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
SEK 19.14+SEK 0.12 (+0.63%)
Swedencare AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
SEK 0.78-SEK 0.00 (-0.64%)
Intervacc AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 46.65% below the high.
